Third Harmonic Bio Inc. (THRD NASDAQ) stock market data APIs
$5.1757
-0.06(-1.2%)
as of May 8, 2025
Third Harmonic Bio Inc. Financial Data Overview
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Prev. Close
5.1757
Open
5.1148
High
5.1253
Low
5.0888
52 wk Range
3.18-16.94
Market Cap
233 M
Shares Outstanding
45 109 K
EPS
-0.29
Beta
2.242
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Third Harmonic Bio Inc. data using free add-ons & libraries
Get Third Harmonic Bio Inc. Fundamental Data
Third Harmonic Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -58 823 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-27
- EPS/Forecast: -0.33
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Third Harmonic Bio Inc. News
New
Here’s Why Third Harmonic Bio (THRD) Fell in Q1
1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned (3.6)% net in the first quarter compared to...
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution ex...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across...
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with cash and cash equivalents totaling $273.9 million...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
